Veradermics Files for $100 Million IPO to Advance Oral Minoxidil Hair Loss Treatment

Veradermics, a Phase 3-ready biotech developing an oral extended-release minoxidil (VDPHL01) for male and female pattern hair loss, filed with the SEC on January 9, 2026, to raise up to $100 million in an IPO.1

The company plans to list on the NYSE under the ticker symbol MANE, with Jefferies, Leerink Partners, Citi, and Cantor Fitzgerald as joint bookrunners.134

IPO proceeds will fund advancement of VDPHL01 through Phase 3 trials, NDA submission, commercialization, supply chain, and doctor education.12

Veradermics has completed enrollment in a 519-patient Phase 2-3 trial for males and initiated two Phase 3 trials for 498 males and 552 females.1

Founded in 2019 in New Haven, CT, the company raised $150 million in Series C funding in October 2025.12

Sources:

1. https://www.renaissancecapital.com/IPO-Center/News/116068/Hair-loss-biotech-Veradermics-files-for-a-$100-million-IPO

2. https://www.biospace.com/business/veradermics-eikon-eye-public-market-debut-as-ipo-tap-opens

3. https://wtaq.com/2026/01/09/biopharmaceutical-firm-veradermics-files-for-us-ipo/

4. https://www.tradingview.com/news/tradingview:d8ac31a40cbda:0-veradermics-dermatology-biopharma-focused-on-hair-loss-files-for-nyse-ipo/